Navigation Links
EuroPCR 2014 examines whether science translates into practice with new session format
Date:5/22/2014

22 May 2014, Paris, France: The value of analysing published clinical trials and the benefit of informed discussion were highlighted yesterday when the ACCOAST trial data were discussed in a new session formatWill this trial change my practice? at EuroPCR 2014. ACCOAST trial results demonstrate that pre-treatment with prasugrel in NSTEMI patients undergoing percutaneous coronary intervention (PCI) is inferior to treatment with the drug after angiography. Several other trials are also being scrutinised in the same format, which ends with a discussion with the audience members on whether the trial results would change their practice or not.

Speaking on the value of the session format, panellist Andreas Baumbach, University of Bristol, UK, said: "There is a need to translate what we read in published journals as trials, ie. the science, to what it means for the practitioner on a daily basis. What does it actually mean when a trial says that this treatment is better, or not, than another one. What does this information finally mean for the patient I am treating? This format is trying to get knowledgeable people, including a trialist, to talk about the specifics of the trial as it is published in order to tease out the data from it that are most relevant for our practice."

The session encourages practitioners to compare the population treated in the trial to the population they treat in daily practice. It also encourages practitioners to question whether the technique used is comparable to the one they employ, and to analyse the endpoints that have been chosen in the trial in order to see if they are relevant for patients.

The ACCOAST trial evaluated the effect of administering the P2Y12 antagonist prasugrel at the time of diagnosis versus administering it after the coronary angiography, if percutaneous coronary intervention (PCI) was indicated. Investigators studied 4,033 patients with NSTE acute coronary syndromes and a positive troponin level who were
'/>"/>

Contact: Isabelle Uzielli
iuzielli@europcr.com
EuroPCR
Source:Eurekalert

Page: 1 2

Related medicine news :

1. CRF will Provide updates on several key cardiovascular trials at EuroPCR
2. New ESC-EACTS guidelines on myocardial revascularization to be released at EuroPCR 2014
3. EuroPCR 2014 showcases technological advances in complex cardiovascular interventions
4. Personalizing revascularization strategy for STEMI patients is vital, EuroPCR panel finds
5. Study examines medicare use for Mohs micrographic surgery and surgical excision for skin cancer
6. Study examines drug regimen for the treatment of non-small cell lung cancer among older patients
7. Study examines adverse effects among different radiation therapies for prostate cancer
8. LA BioMeds Dr. John Tsuang examines effects of Ibudilast and metamphetamines
9. Study examines benefit of follow-up CT when abdominal ultrasound inconclusive
10. Research examines when benefits of screening mammography outweigh the harms for women in their 40s
11. Study examines necessity of additional imaging in PET/CT oncologic reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... (PRWEB) March 27, 2015 The federal ... that allege the statin medication increases the risk that ... Pfizer Inc.’s Motion to Dismiss four individual cases that ... Case Management Order issued in the U.S. District Court, ... determined that the dismissals were warranted because the plaintiffs ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Bleeding ... patients undergoing percutaneous coronary intervention (PCI), resulting in ... observed a “risk-treatment paradox,” in which the highest-risk ... treatment are treated less often with bleeding avoidance ... Saint Luke’s Mid America Heart Institute asked the ...
(Date:3/27/2015)... Healthpointe is proud to announce that ... now treating knee and hip joint disorders in practice ... Beach, and La Mirada. Dr. Stanley Katz specializes in ... joint disorders as well as chronic conditions such as ... his patients back to their normal lives. Many ...
(Date:3/27/2015)... New York, NY (PRWEB) March 27, 2015 Ticket ... Live in Concert in 2015. After a phenomenal and ... hit show "Nashville" will be going out on tour again in ... The tour gets underway on April 29th in New York ... Phoenix, AZ at the Comerica Theatre on May 10th. , Fans ...
(Date:3/27/2015)... While deep learning was the topic of ... (GTC) , the CEO of one start-up spoke passionately about ... lifespan well beyond the generally-agreed ceiling of 120 years. , ... one of 12 companies recognized as the hottest GPU-powered startups ... GTC Emerging Companies Summit have business models focused ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3
... ORLANDO, Fla. Results of a study presented at the ... credence to the idea that improving quality of life affects ... cancer. Researchers know that telomeres shorten and deteriorate with ... length. "We are trying to understand the interconnections between ...
... , FRIDAY, April 1 (HealthDay News) -- At-home pregnancy tests ... on the way and if it is time to call ... offer tantalizing clues about future health risks -- are still ... results may puzzle or even panic consumers who don,t seek ...
... use has been linked to thicker arteries, possibly contributing to ... of twin veterans. The data is being presented Tuesday, April ... Orleans. Depression can heighten the risk for heart disease, ... is separate and independent from depression itself, says first author ...
... Germany, Saturday 02 April 2011: Exciting new data presented ... quadruple therapy in chronic hepatitis C (HCV) patients suppressed ... 100% rate of sustained virological response - undetectable HCV ... the quadruple therapy study, HCV patients were given four ...
... Fla. The combination of two compounds that inhibit ... showing promise in an ongoing Phase I trial, according ... 2011, held here April 2-6. The research, ... GDC-0973, which inhibits MEK1/2 and GDC-0941, which inhibits PI3K. ...
... (HealthDay News) -- Updated guidelines to keep children happy, safe ... week by the American Academy of Pediatrics. When deciding ... and overall well-being, to ensure their child can effectively participate ... and mentally prepare their child for camp, and team with ...
Cached Medicine News:Health News:Chronic stress of cancer causes accelerated telomere shortening 2Health News:Do At-Home Genetic Tests Tell Too Much and Explain Too Little? 2Health News:Do At-Home Genetic Tests Tell Too Much and Explain Too Little? 3Health News:Antidepressants linked to thicker arteries 2Health News:Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment 2Health News:Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity 2Health News:Pediatrics Group Offers Guidelines to Keep Young Campers Safe, Healthy 2
(Date:3/26/2015)... PASADENA, Calif. , March 26, 2015 ... San Gabriel Valley to perform transcatheter aortic valve replacement ... TAVR procedure is a revolutionary new way to replace ... use of a heart lung machine. The ... heart team led by Azhil ( Alex) Durairaj , ...
(Date:3/26/2015)... VANCOUVER, British Columbia, March 26, 2015  OncoGenex ... a summary of clinical developments and announced fourth ... Clinical Developments and Anticipated Near-term MilestonesCustirsen ... and Teva agreed to negotiate the termination of ... Negotiations of the final termination agreement are ongoing. ...
(Date:3/26/2015)... March 26, 2015 According to ... Procedure Volume, Technology (RF, Microwave, Cryoablation, Others), Department (Interventional ... Cancer, Bone Metastasis) - Global Forecasts to 2019", published ... reach around $462.0 Million growing at a CAGR of ... tables and 57 figures spread through 195 pages and ...
Breaking Medicine Technology:Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Tumor Ablation Market Worth $462.0 Million by 2019 2Tumor Ablation Market Worth $462.0 Million by 2019 3Tumor Ablation Market Worth $462.0 Million by 2019 4
... 2011 Cardica, Inc. (Nasdaq: CRDC ) today ... 30, 2011. Cardica,s management will host a conference call at ... and provide an update on the company,s business. ... Dr. Swanstrom, a world-renowned key opinion leader in laparoscopic surgery, ...
... ($ in millions, except per share data, unaudited)ItemQ3 2011Q3 ... Net Product Revenue , $112.9 , 16.9% increaseNaglazyme Net ... Product Revenue* , $23.0 , $16.5Kuvan Net Product ... , $3.5 , 59.1% increaseGAAP Net Income (Loss) , ...
Cached Medicine Technology:Cardica Announces Fiscal 2012 First Quarter Financial Results 2Cardica Announces Fiscal 2012 First Quarter Financial Results 3Cardica Announces Fiscal 2012 First Quarter Financial Results 4Cardica Announces Fiscal 2012 First Quarter Financial Results 5Cardica Announces Fiscal 2012 First Quarter Financial Results 6BioMarin Announces Third Quarter 2011 Financial Results 2BioMarin Announces Third Quarter 2011 Financial Results 3BioMarin Announces Third Quarter 2011 Financial Results 4BioMarin Announces Third Quarter 2011 Financial Results 5BioMarin Announces Third Quarter 2011 Financial Results 6BioMarin Announces Third Quarter 2011 Financial Results 7BioMarin Announces Third Quarter 2011 Financial Results 8BioMarin Announces Third Quarter 2011 Financial Results 9BioMarin Announces Third Quarter 2011 Financial Results 10BioMarin Announces Third Quarter 2011 Financial Results 11BioMarin Announces Third Quarter 2011 Financial Results 12BioMarin Announces Third Quarter 2011 Financial Results 13
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: